Table Filtering
Submissions
GlyTouCan
Glycan Structure Repository
GlyComb
Glycoconjugate Repository
GlycoPOST
Glycomics MS raw data Repository
UniCarb-DR
Glycomics MS Repository for glycan annotations from GlycoWorkbench
LM-GlycoRepo
Repository for lectin-assisted multimodality data
All Resources
Genes / Proteins / Lipids Glycans / Glycoconjugates Glycomes Pathways / Interactions / Diseases / Organisms
GlycoNAVI Proteins
GlycoNAVI-Proteins is dataset of glycan and protein information. This is the content of GlycoNAVI.
| Source | Last Updated |
|---|---|
| GlycoNAVI Proteins | January 08, 2025 |
| PDB ID ▲ | UniProt ID | Title | Descriptor |
|---|---|---|---|
| 8CWV | P0DTC2 | Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutralizing nanobody 2-31 and a human antibody CC12.1 Fab | |
| 8CWV | 8CWV | Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutralizing nanobody 2-31 and a human antibody CC12.1 Fab | |
| 8CX3 | Q13421 | Crystal structure of full-length mesothelin | |
| 8CXI | A0A142DS37 | Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy | |
| 8CXI | Q9H9E1 | Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy | |
| 8CXI | A0A1S6LXE0 | Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy | |
| 8CXI | 8CXI | Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy | |
| 8CXN | P0DTC2 | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-57 | |
| 8CXN | 8CXN | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-57 | |
| 8CY7 | P0DTC2 | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34 | |
| 8CY7 | 8CY7 | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34 | |
| 8CYA | P0DTC2 | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-67 | |
| 8CYA | 8CYA | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-67 | |
| 8CYB | P0DTC2 | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-8 | |
| 8CYB | 8CYB | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-8 | |
| 8CYH | 8CYH | Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics | |
| 8CYH | Q13421 | Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics | |
| 8CZZ | A0A6C0ZY47 | Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer with LMHS mutations in complex with Temsavir, 8ANC195, and 10-1074 | |
| 8CZZ | 8CZZ | Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer with LMHS mutations in complex with Temsavir, 8ANC195, and 10-1074 | |
| 8D0O | Q9Y231 | Human alpha1,3-fucosyltransferase FUT9, heavy atom derivative | |
| 8D0P | Q9Y231 | Human FUT9, unliganded | |
| 8D0Q | Q9Y231 | Human FUT9 bound to GDP-CF3-Fucose and H-Type 2 | |
| 8D0R | Q9Y231 | Human FUT9 bound to GDP and H-Type 2 | |
| 8D0S | Q9Y231 | Human FUT9 bound to GDP and LNnT | |
| 8D0U | Q9Y231 | Human FUT9 bound to GDP | |
| 8D0W | Q9Y231 | Human FUT9 bound to H-Type 2 | |
| 8D0X | Q9Y231 | Human FUT9 bound to LNnT | |
| 8D0Y | 8D0Y | Crystal Structure of HIV-1 BG505 SOSIPv8 Trimer in Complex with CD4bs targeting antibody 21N13 and interface targeting antibody 35O22 at 4.7 Angstrom | |
| 8D0Z | P0DTC2 | S728-1157 IgG in complex with SARS-CoV-2-6P-Mut7 Spike protein (focused refinement) | |
| 8D0Z | 8D0Z | S728-1157 IgG in complex with SARS-CoV-2-6P-Mut7 Spike protein (focused refinement) | |
| 8D21 | Q6WG00 | Cryo-EM structure of the VRC321 clinical trial, vaccine-elicited, human antibody 1B06 in complex with a stabilized NC99 HA trimer | |
| 8D21 | Q289M7 | Cryo-EM structure of the VRC321 clinical trial, vaccine-elicited, human antibody 1B06 in complex with a stabilized NC99 HA trimer | |
| 8D21 | 8D21 | Cryo-EM structure of the VRC321 clinical trial, vaccine-elicited, human antibody 1B06 in complex with a stabilized NC99 HA trimer | |
| 8D2S | Q6DEJ6 | Zebrafish MFSD2A isoform B in inward open ligand bound conformation | |
| 8D2S | 8D2S | Zebrafish MFSD2A isoform B in inward open ligand bound conformation | |
| 8D2T | Q6DEJ6 | Zebrafish MFSD2A isoform B in inward open ligand-free conformation | |
| 8D2T | 8D2T | Zebrafish MFSD2A isoform B in inward open ligand-free conformation | |
| 8D2U | Q6DEJ6 | Zebrafish MFSD2A isoform B in inward open ligand 1A conformation | |
| 8D2U | 8D2U | Zebrafish MFSD2A isoform B in inward open ligand 1A conformation | |
| 8D2V | Q6DEJ6 | Zebrafish MFSD2A isoform B in inward open ligand 1B conformation | |
| 8D2V | 8D2V | Zebrafish MFSD2A isoform B in inward open ligand 1B conformation | |
| 8D2W | Q6DEJ6 | Zebrafish MFSD2A isoform B in inward open ligand 2B conformation | |
| 8D2W | 8D2W | Zebrafish MFSD2A isoform B in inward open ligand 2B conformation | |
| 8D2X | Q6DEJ6 | Zebrafish MFSD2A isoform B in inward open ligand 3C conformation | |
| 8D2X | 8D2X | Zebrafish MFSD2A isoform B in inward open ligand 3C conformation | |
| 8D3A | 8D3A | Crystal Structure of DH475 Fab in complex with Man9 | |
| 8D3C | P04275 | VWF tubule derived from monomeric D1-A1 | |
| 8D3D | P04275 | VWF tubule derived from dimeric D1-A1 | |
| 8D3T | A0A2K2AMS7 | Crystal structure of GalS1 from Populus trichocarpas | |
| 8D3Z | A0A2K2AMS7 | Crystal structure of GalS1 in complex with Manganese from Populus trichocarpas |
